Rainbow Children's Medicare reported a significant increase in Q4 EBITDA, reaching ₹145 million – a growth of approximately 23% year-on-year. The improved earnings margin stands at 31.4%, marking a slight uptick compared to the previous year.

Rainbow Children's Medicare achieves a new high in Q4 revenue at INR 459.9 crore, setting a promising trend. The company is aiming to increase its capacity with a planned addition of 900 beds by FY29.

Rainbow Children's Medicine shares their Q4 results for FY26, presenting both standalone and combined data. With a presence spanning 241 hospitals across nine major cities, the company focuses on delivering top-tier pediatric and maternity care services nationwide.

Rainbow Children's Medicine plans to announce their FY26 results and decide on a potential dividend on May 23, 2026. Investors should note that trading for the company's securities is currently closed but will resume 48 hours after the announcement.

Rainbow Children's Medicare experienced a significant block trade on the NSE for approximately INR 17.5 crore, with each share trading at around INR 1,290.9.

Rainbow Children's Medicare expands its operations in Bengaluru with a new 60-bed hospital, now boasting a total of 2435 beds. Additionally, they've introduced an IVF center in Mahadevapura, funded through internal resources amounting to 52 crores.

Rainbow Children's Medicare expands its operations with a new 60-bed hospital and IVF center, increasing its bed capacity to 2,435 beds. The expansion project, located in HRBR Layout and Mahadevpura, comes at an estimated cost of ₹52 crore.

HSBC keeps a positive stance towards Rainbow Children's Medicare, recommending buyers. The target price is set at ₹1,400, reflecting optimism due to consistent elective procedures, investments, and steady hospital operations in Q4 FY26.